Compatibility and Immunogenicity of a Short Specific Immunotherapy (SIT) in Contrast to Classic Specific Immunotherapy

Compatibility and Immunogenicity of a Short Specific Immunotherapy (SIT) in Contrast to Classic Specific Immunotherapy in a Randomized Study Depending on Mite-Depot Supplement in Children and Adolescents With Allergic Bronchial Asthma.

We wanted to examine the immunogenicity and safety of a shortened specific immunotherapy in contrast to the standard specific immunotherapy.

Therefore, we challenged 12 patients for 14 weeks with the standard specific scheme and 22 patients for 6 weeks with the shortened scheme.

see above

Inclusion Criteria:

• informed consent of patient and/or parents
• age >6 and <18 years
• bronchial asthma I° or II°
• allergy on house dust-mite

Exclusion Criteria:

• age <6 and >18 years
• vital capacity <80% or FEV1 <70%
• pregnancy
• inhalative or systemic steroid use
• bronchial asthma III° or IV°
• heavy exacerbation during the last 3 months